EPISODE · Mar 21, 2025 · 44 MIN
Breast Cancer
from Ninja Nerd · host Ninja Nerd
Send us Fan MailNinja Nerds,Welcome to the Ninja Nerd Podcast with Zach and Rob! In this episode, we explore Breast Cancer's pathogenesis, risk factors, and the latest advancements in screening, diagnosis, and treatment. We break down the molecular subtypes of breast cancer, including hormone receptor-positive, HER2-positive, and triple-negative disease, and discuss their clinical implications and targeted therapies.Our discussion covers essential diagnostic tools, such as mammography, breast ultrasound, MRI, and core needle biopsy, emphasizing how to interpret imaging findings and pathology reports. We also analyze prognostic factors, including TNM staging, to guide medical therapies.Additionally, we explore cutting-edge treatment strategies, including endocrine therapy, HER2-targeted monoclonal antibodies (e.g., trastuzumab), chemotherapy regimens, and advancements in immunotherapy for triple-negative disease. We also discuss surgical options, radiation therapy, and complications such as lymphedema and cardiotoxicity from trastuzumab.Whether you’re studying for boards, preparing for clinical rotations, or just passionate about oncology, this episode is packed with high-yield pearls you don’t want to miss!Join the Millionaires in Medicine Club!Enjoy the episode and support us below! 🎙🔥Support the show
What this episode covers
Send us Fan Mail Ninja Nerds, Welcome to the Ninja Nerd Podcast with Zach and Rob! In this episode, we explore Breast Cancer's pathogenesis, risk factors, and the latest advancements in screening, diagnosis, and treatment. We break down the molecular subtypes of breast cancer, including hormone receptor-positive, HER2-positive, and triple-negative disease, and discuss their clinical implications and targeted therapies. Our discussion covers essential diagnostic tools, such as mammography, bre...
NOW PLAYING
Breast Cancer
No transcript for this episode yet
Similar Episodes
Mar 27, 2026 ·100m
Mar 12, 2026 ·45m
Mar 3, 2026 ·19m
Dec 25, 2025 ·82m
Oct 30, 2025 ·63m